# Lupus Nephritis FDA approvals and PDUFA dates

Canonical: https://sec-api.dev/indications/lupus-nephritis

> 6 upcoming FDA catalysts in lupus Nephritis: Saphnelo (anifrolumab, AZN) on Feb to May 2027 (topline data readout); Saphnelo (anifrolumab, AZN) on February 2027 (primary completion); ianalumab s.c. q4w (NVS) on Sep to Dec 2027 (topline data readout); ianalumab s.c. q4w (NVS) on September 2027 (primary completion); and 2 more.

Data as of November 16, 2026 (snapshot 20261116T222116Z). Every date quotes the SEC filing or FDA page it came from. Date precision: exact day, quarter only, month only.

**Free:** every drug page and the next 30 days of the FDA calendar, no account. Calendar API, alerts when a date moves, and full history: https://sec-api.dev/pricing . Free API key: https://sec-api.dev/sign-up?ref=ai-claudebot

## Catalysts

| Date | Event | Ticker | Indication | Status | Source sentence |
| --- | --- | --- | --- | --- | --- |
| July 2, 2025 | [Efgartigimod iv primary completion](https://sec-api.dev/pdufa/efgartigimod-iv) | ARGX | Lupus Nephritis | completed | "NCT05810948 (A Study to Assess Effectiveness and Safety of Efgartigimod in Chinese Patients With Lupus Nephritis (ZL-1103-013)): Overall Status COMPLETED; Phase PHASE2; Primary Completion 2025-07-02 (ACTUAL); Lead Sponsor argenx." ([ClinicalTrials.gov](https://clinicaltrials.gov/study/NCT05810948)) |
| March 19, 2026 | [Iptacopan (part 1) primary completion](https://sec-api.dev/pdufa/iptacopan-part-1) | NVS | Lupus Nephritis | withdrawn | "NCT05268289 (Study of Efficacy and Safety of LNP023 in Participants With Active Lupus Nephritis Class III-IV, +/- V): Overall Status TERMINATED; Phase PHASE2; Primary Completion 2026-03-19 (ACTUAL); Lead Sponsor Novartis Pharmaceuticals." ([ClinicalTrials.gov](https://clinicaltrials.gov/study/NCT05268289)) |
| Feb to May 2027 | [Saphnelo (anifrolumab) topline data readout](https://sec-api.dev/pdufa/anifrolumab) | AZN | Lupus Nephritis | scheduled | "NCT05138133 (Phase 3 Study of Anifrolumab in Adult Patients With Active Proliferative Lupus Nephritis): Overall Status ACTIVE_NOT_RECRUITING; Phase PHASE3; Primary Completion 2027-02-23 (ESTIMATED); Lead Sponsor AstraZeneca." ([ClinicalTrials.gov](https://clinicaltrials.gov/study/NCT05138133)) |
| February 2027 | [Saphnelo (anifrolumab) primary completion](https://sec-api.dev/pdufa/anifrolumab) | AZN | Lupus Nephritis | scheduled | "NCT05138133 (Phase 3 Study of Anifrolumab in Adult Patients With Active Proliferative Lupus Nephritis): Overall Status ACTIVE_NOT_RECRUITING; Phase PHASE3; Primary Completion 2027-02-23 (ESTIMATED); Lead Sponsor AstraZeneca." ([ClinicalTrials.gov](https://clinicaltrials.gov/study/NCT05138133)) |
| Sep to Dec 2027 | [Ianalumab s.c. q4w topline data readout](https://sec-api.dev/pdufa/ianalumab-s-c-q4w) | NVS | Lupus Nephritis | scheduled | "NCT05126277 (Safety, Efficacy and Tolerability of Ianalumab Versus Placebo, Combination With SoC Therapy, in Participants With Active Lupus Nephritis): Overall Status ACTIVE_NOT_RECRUITING; Phase PHASE3; Primary Completion 2027-09-21 (ESTIMATED); Lead Sponsor Novartis Pharmaceuticals." ([ClinicalTrials.gov](https://clinicaltrials.gov/study/NCT05126277)) |
| September 2027 | [Ianalumab s.c. q4w primary completion](https://sec-api.dev/pdufa/ianalumab-s-c-q4w) | NVS | Lupus Nephritis | scheduled | "NCT05126277 (Safety, Efficacy and Tolerability of Ianalumab Versus Placebo, Combination With SoC Therapy, in Participants With Active Lupus Nephritis): Overall Status ACTIVE_NOT_RECRUITING; Phase PHASE3; Primary Completion 2027-09-21 (ESTIMATED); Lead Sponsor Novartis Pharmaceuticals." ([ClinicalTrials.gov](https://clinicaltrials.gov/study/NCT05126277)) |
| August 2028 | [AUCATZYL (obecabtagene autoleucel) primary completion](https://sec-api.dev/pdufa/obecabtagene-autoleucel) | AUTL | Lupus Nephritis | scheduled | "NCT07053800 (Obe-cel in Severe, Refractory Systemic Lupus Erythematosus (SLE) With Active Lupus Nephritis (LN)): Overall Status RECRUITING; Phase PHASE2; Primary Completion 2028-08 (ESTIMATED); Lead Sponsor Autolus Limited." ([ClinicalTrials.gov](https://clinicaltrials.gov/study/NCT07053800)) |
| Aug to Nov 2028 | [AUCATZYL (obecabtagene autoleucel) topline data readout](https://sec-api.dev/pdufa/obecabtagene-autoleucel) | AUTL | Lupus Nephritis | scheduled | "NCT07053800 (Obe-cel in Severe, Refractory Systemic Lupus Erythematosus (SLE) With Active Lupus Nephritis (LN)): Overall Status RECRUITING; Phase PHASE2; Primary Completion 2028-08 (ESTIMATED); Lead Sponsor Autolus Limited." ([ClinicalTrials.gov](https://clinicaltrials.gov/study/NCT07053800)) |

## Drugs

- [Efgartigimod iv](https://sec-api.dev/pdufa/efgartigimod-iv) (ARGX)
- [Iptacopan (part 1)](https://sec-api.dev/pdufa/iptacopan-part-1) (NVS)
- [Saphnelo (anifrolumab)](https://sec-api.dev/pdufa/anifrolumab) (AZN)
- [Ianalumab s.c. q4w](https://sec-api.dev/pdufa/ianalumab-s-c-q4w) (NVS)
- [AUCATZYL (obecabtagene autoleucel)](https://sec-api.dev/pdufa/obecabtagene-autoleucel) (AUTL)

## Feeds and downloads

- Subscribe (iCal): https://sec-api.dev/indications/lupus-nephritis.ics
- Next 30 days as CSV: https://sec-api.dev/fda-calendar.csv . JSON: https://sec-api.dev/fda-calendar.json . All events (iCal): https://sec-api.dev/fda-calendar.ics
- New or moved PDUFA dates: https://sec-api.dev/pdufa-dates/feed.xml (RSS), https://sec-api.dev/pdufa-dates/feed.json (JSON Feed)
- FDA approvals: https://sec-api.dev/fda-approvals-today/feed.xml (RSS), https://sec-api.dev/fda-approvals-today/feed.json (JSON Feed)
- License: CC BY 4.0 for the public 30-day window (https://sec-api.dev/biotech/license.txt). Full history: https://sec-api.dev/pricing

## Cite this page

sec-api.dev. "Lupus Nephritis FDA approvals and PDUFA dates." Biotech catalyst calendar, data as of November 16, 2026 (snapshot 20261116T222116Z). https://sec-api.dev/indications/lupus-nephritis

```bibtex
@misc{secapidev_indications_lupus_nephritis_20261116,
  title        = {Lupus Nephritis FDA approvals and PDUFA dates},
  author       = {{sec-api.dev}},
  year         = {2026},
  month        = {nov},
  howpublished = {\url{https://sec-api.dev/indications/lupus-nephritis}},
  note         = {Biotech catalyst calendar, data as of 2026-11-16, snapshot 20261116T222116Z. Compiled from SEC EDGAR filings, FDA and ClinicalTrials.gov; each date quotes its source.}
}
```

```json
{"type":"dataset","id":"secapidev_indications_lupus_nephritis_20261116","title":"Lupus Nephritis FDA approvals and PDUFA dates","publisher":"sec-api.dev","URL":"https://sec-api.dev/indications/lupus-nephritis","issued":{"date-parts":[[2026,11,16]]},"version":"20261116T222116Z","license":"https://creativecommons.org/licenses/by/4.0/","note":"Compiled from SEC EDGAR filings, FDA and ClinicalTrials.gov; each date quotes its source."}
```

---
Independent. Not affiliated with, endorsed by, or sponsored by the U.S. Food and Drug Administration or the U.S. Securities and Exchange Commission. Dates are as stated by sponsors and FDA; the FDA can act before or after a target date. Not investment advice.
